Imaging of Non— or Very Subtle Contrast-Enhancing Malignant Gliomas with [C]-Methionine Positron Emission Tomography

Abstract

In patients with World Health Organization (WHO) grade III glioma with a lack of or minimal (2 lesion and reached beyond it (in 10 of 12 MRIs/MET-PET scans). The present data suggest that in patients with WHO grade III glioma with minimal or a lack of contrast enhancement, MET-PET delineates metabolically active tumor tissue. These findings support the use of combined PET-MRI with radiolabeled amino acids (eg, MET) for the delineating of the true extent of active tumor in the diagnosis and treatment planning of patients with gliomas.